Dapagliflozin

Overview

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used to manage type 2 diabetes mellitus. It helps improve glycemic control and has cardiovascular benefits.

API suppliers (20)

Suppliers of Dapagliflozin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• Biocon LimitedIndia1 active DMF
• ZAKLADY FARMACEUTYCZNE POLPHARMA SA1 active DMF
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• RAKS PHARMA PVT LTDIndia1 active DMF
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
• Bionpharma1 active DMF
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• Jiangsu Hansoh Pharmaceutical Group Company LimitedChina1 active DMF GMP on record
• Micro Labs Usa1 active DMF
• HARMAN FINOCHEM LTDIndia1 active DMF GMP on record
• LEE PHARMA LTDIndia1 active DMF GMP on record
• OPTIMUS DRUGS PRIVATE LTDIndia1 active DMF
• Wisdom Pharmaceutical Co., LtdChina1 active DMF
• Porton Pharma Solutions Ltd.China1 active DMF
• Granules India LimitedIndia1 active DMF GMP on record
• Zhejiang Jingsheng Pharmaceutical Co., Ltd.China1 active DMF
• LINHAI TIANYU PHARMACEUTICAL CO LTDChina1 active DMF
• Laurus Labs LimitedIndia1 active DMF GMP on record
• ZENJI PHARMACEUTICALS (SUZHOU) LTDChina1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (32 approved US products), the latest listed US patent on Dapagliflozin expires 1 Oct 2041 and exclusivity 12 Dec 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas